169 related articles for article (PubMed ID: 29784677)
1. Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
Lingvay I; Leiter LA
Circulation; 2018 May; 137(21):2200-2202. PubMed ID: 29784677
[No Abstract] [Full Text] [Related]
2. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
Scheen AJ; Paquot N
Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
[TBL] [Abstract][Full Text] [Related]
3. [Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system].
Fiorentino TV; Sesti G
G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):13S-19. PubMed ID: 28151517
[TBL] [Abstract][Full Text] [Related]
4. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
McReelis KD; Lovshin JA
Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
[No Abstract] [Full Text] [Related]
5. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Simó R; Hernández C
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
[No Abstract] [Full Text] [Related]
6. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
Athyros VG; Katsiki N; Tentolouris N
Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
[No Abstract] [Full Text] [Related]
7. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
Scheen AJ; Wallemacq C; Jandrain B; Ernest P
Rev Med Suisse; 2016 Aug; 12(527):1370-1375. PubMed ID: 28671791
[TBL] [Abstract][Full Text] [Related]
8. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
Ingelfinger JR; Rosen CJ
N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286
[No Abstract] [Full Text] [Related]
9. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
Chudleigh RA; Bain S
Expert Opin Drug Saf; 2017 May; 16(5):627-635. PubMed ID: 28387138
[TBL] [Abstract][Full Text] [Related]
10. London buses: A cardiovascular outcome trial equivalent?
Grant PJ
Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
[No Abstract] [Full Text] [Related]
11. Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
Cusi K
Curr Opin Lipidol; 2016 Dec; 27(6):633-635. PubMed ID: 27805974
[No Abstract] [Full Text] [Related]
12. Obesity Week 2016 Annual Meeting.
Marathe PH; Dove AE; Gao HX; Odeh SA; Close KL
J Diabetes; 2017 Mar; 9(3):215-218. PubMed ID: 27883282
[No Abstract] [Full Text] [Related]
13. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Scheen AJ; Piérard L; Krzesinski JM; Paquot N
Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
[TBL] [Abstract][Full Text] [Related]
14. Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
Thompson J; Schacht S; Rothenberg F
Cardiol Clin; 2019 Aug; 37(3):335-343. PubMed ID: 31279427
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
Arbel R; Hammerman A; Azuri J
Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890
[TBL] [Abstract][Full Text] [Related]
16. Results from Cardiovascular Outcome Trials in Diabetes.
Muñoz Torres M; Muñoz Garach A
Endocrinol Nutr; 2016; 63(7):317-9. PubMed ID: 27324936
[No Abstract] [Full Text] [Related]
17. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
18. A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
Rossello X; Yellon DM
Int J Cardiol; 2017 Feb; 228():198-200. PubMed ID: 27865185
[TBL] [Abstract][Full Text] [Related]
19. Antihyperglycemic medications for cardiovascular disease risk reduction.
Goldman JD
Am J Manag Care; 2018 Aug; 24(13 Suppl):S273-S278. PubMed ID: 30160394
[TBL] [Abstract][Full Text] [Related]
20. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
Kaul S
Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
